Pyxis Oncology (PYXS) Net Margin (2024 - 2025)
Pyxis Oncology's (PYXS) quarterly Net Margin came in at 2.75% in Q4 2025, up 99.58% quarter-over-quarter from 650.85% in Q2 2025.
Powered by 
Analysis
Pyxis Oncology (PYXS) Net Margin (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Net Margin for 2 consecutive years, with 2.75% the latest figure, recorded in Q4 2025.
- On a quarterly basis, Net Margin changed N/A year-over-year to 2.75% in Q4 2025; TTM through Jun 2026 was 476.3%, a 295636.0% increase from a year earlier, with the FY2025 full-year figure at 446.08%, up 3287.0% from the prior year.
- Net Margin was 2.75% for Q4 2025 at Pyxis Oncology, up from 650.85% in the prior quarter.
- Over five years, Net Margin peaked at 2.75% in Q4 2025 and troughed at 650.85% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.74 Bn | 192.75 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 179.96 Bn | 176.78 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 131.20 Bn | 123.35 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.05 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.08 Bn | 29.78 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.91 Bn | 30.62 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.22 Bn | 29.22 Bn | 1.16 Mn | -20,152.98% |
| 10 | Pyxis Oncology | 206.05 Mn | 173.06 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -2.75% |
| Jun 30, 2025 | -650.85% |
| Mar 31, 2024 | -24.80% |